www.prokarium.com Open in urlscan Pro
89.34.18.57  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Technology
 * Team
 * Pipeline
 * News
 * Careers
 * Contact

Menu
 * Technology
 * Team
 * Pipeline
 * News
 * Careers
 * Contact

 * Technology
 * Team
 * Pipeline
 * News
 * Careers
 * Contact

Menu
 * Technology
 * Team
 * Pipeline
 * News
 * Careers
 * Contact


PIONEERING MICROBIAL IMMUNOTHERAPIES

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is
designed to unlock the next level of immuno-oncology by building on the most
recent advances in cancer immunology. Prokarium’s lead program is focused on
transforming the treatment paradigm in bladder cancer by orchestrating
immune-driven, long-lasting antitumor effects.




TECHNOLOGY

In this adaption of our platform technology, we leverage proprietary genetic
engineering interventions to build on the natural ability of our bacterial
strains to seek out and colonise solid tumours. We have developed attenuated
strains capable of targeting tumours without causing pathology in normal
tissues. These strains are also capable of delivering specific immunostimulatory
cargo aimed at activating the patient’s immune system to destroy tumours.




TEAM

 * Team
 * Board of Directors
 * Advisors


KRISTEN ALBRIGHT

CEO


LIVIJA DEBAN

CSO



JULIA JONES

CFO


JOSEFIN-BEATE (JOSI) HOLZ

CMO


THOMAS ELDERED

Chairman


STEVE CHATFIELD

Director



ALLAN P. JARVIS

Director



KHALID AL-SALEH

Director



SANGWOO LEE

Director


HYAM LEVITSKY

Director




TED FJÄLLMAN

Director



HYAM LEVITSKY

Immunotherapy Advisor


DAVID HOLDEN

Salmonella Advisor



GEOFF KITSON

Medical Advisor


BRIGITTE KÖHN

CMC Advisor




THERAPEUTIC


PROPHYLACTIC


PIPELINE


INDICATION


PROGRAM


DRUG DISCOVERY


PRECLINICAL


EARLY CLINICAL DEVELOPMENT


LATE CLINICAL DEVELOPMENT


NMIBC

+

NMIBC Therapeutic

Bladder cancer represents 5% of all new cancer cases in the US and accounts for
550,000 new cases yearly worldwide. The clinical staging is determined by the
depth of invasion into the bladder wall and more than 70% of cases are diagnosed
at an early-stage, also known as Non Muscle Invasive Bladder Cancer (NMIBC).
Despite the early diagnosis, the only approved therapies are Bacillus
Calmette–Guérin (BCG), which often faces shortages, and chemotherapy, both
delivered intravescically. Because of its high incidence and the low number of
treatment options, a huge unmet medical need remains in NMIBC.


S. TYPHI




SOLID TUMOURS

+

Undisclosed

Prokarium is investigating the use of engineered bacteria as immunotherapy to
treat solid tumours. Onconella has the ability to sense and kill tumour cells
and, in addition, to boost the natural anti-tumoral activity of the immune
system.


UNDISCLOSED




ENTERIC FEVER

+

S. Typhi and S. Paratyphi A Vaccine

FIH Phase 1 Readout
1H2021

Enteric fever, a preventable illness caused by Salmonella enterica serovars
Typhi and Paratyphi A, is the most common bacterial bloodstream infection in
South Asia. It has been estimated to cause >15 million illnesses and nearly
153,000 deaths worldwide annually.

Entervax™, a novel, oral bivalent vaccine against enteric fever, is based on the
Vaxonella® platform and is the combination of our proprietary strain ZH9
(Salmonella enterica serovar Typhi ZH9), plus a novel strain modified to express
antigens specific to S. Paratyphi A.


ENTERVAX





PIPELINE


PROGRAM


PHASE


NMIBC


S. TYPHI

+

NMIBC Therapeutic

Bladder cancer represents 5% of all new cancer cases in the US and accounts for
550,000 new cases yearly worldwide. The clinical staging is determined by the
depth of invasion into the bladder wall and more than 70% of cases are diagnosed
at an early-stage, also known as Non Muscle Invasive Bladder Cancer (NMIBC).
Despite the early diagnosis, the only approved therapies are Bacillus
Calmette–Guérin (BCG), which often faces shortages, and chemotherapy, both
delivered intravescically. Because of its high incidence and the low number of
treatment options, a huge unmet medical need remains in NMIBC.


PRECLINICAL


THERAPEUTIC


SOLID TUMOURS


UNDISCLOSED

+

Undisclosed

Prokarium is investigating the use of engineered bacteria as immunotherapy to
treat solid tumours. Onconella has the ability to sense and kill tumour cells
and, in addition, to boost the natural anti-tumoral activity of the immune
system.


DRUG DISCOVERY


ENTERIC FEVER


ENTERVAX

+

S. Typhi and S. Paratyphi A Vaccine

FIH Phase 1
1Q2020

Enteric fever, a preventable illness caused by Salmonella enterica serovars
Typhi and Paratyphi A, is the most common bacterial bloodstream infection in
South Asia. It has been estimated to cause >15 million illnesses and nearly
153,000 deaths worldwide annually.

Entervax™, a novel, oral bivalent vaccine against enteric fever, is based on the
Vaxonella® platform and is the combination of our proprietary strain ZH9
(Salmonella enterica serovar Typhi ZH9), plus a novel strain modified to express
antigens specific to S. Paratyphi A.


EARLY CLINICAL DEVELOPMENT


PROPHYLACTIC


COVID-19


SARS-COV-2


DRUG DISCOVERY




NEWS

 * February 26, 2018·


PROKARIUM SECURES $10 MILLION INVESTMENT FROM SAUDI, SWEDISH AND KOREAN
INVESTORS FOR CLINICAL DEVELOPMENT OF REVOLUTIONARY THERMOSTABLE VACCINES

Prokarium closes $10 million Series A round to develop thermostable vaccines.
 * July 25, 2016·


PROKARIUM RECEIVES £2M IN GOVERNMENT CONTRACTS TO DEVELOP NEW VACCINES AGAINST
EMERGING DISEASES AND BIOTERRORIST THREATS

Prokarium has received government funds to develop new vaccines.
 * July 15, 2016·


PROKARIUM AWARDS THE NEWTON FUND FOR THE DEVELOPMENT OF AN ORAL, THERMOSTABLE
ENTERIC FEVER VACCINE: SAVING LIVES AND SUPPORTING TOURISM IN MEXICO

Prokarium has awarded a £0.37m grant to develop an oral, bivalent vaccine
against enteric fever.
 * October 19, 2022·


PROKARIUM STRENGTHENS MANUFACTURING CAPABILITIES WITH APPOINTMENT OF PETER JUUL
MADSEN AS VICE PRESIDENT OF CMC

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company
pioneering the oncology field…
 * October 5, 2022·


PROKARIUM STRENGTHENS PATENT POSITION THROUGH NOTICE OF ALLOWANCE OF US PATENT
FOR IMMUNOTHERAPY PRIME IN COMBINATION WITH CELL THERAPIES

LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the
‘Company’), a biopharmaceutical…
 * March 2, 2022·


PROKARIUM EXERCISES OPTION FOR AN EXCLUSIVE WORLDWIDE LICENSE FOR THE USE OF
SALMONELLA IMMUNOTHERAPY IN THE TREATMENT OF BLADDER CANCER

LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering
the oncology field…
 * January 26, 2022·


PROKARIUM EXPANDS R&D CAPABILITIES WITH LONDON BIOFOUNDRY TO DEEPEN MICROBIAL
IMMUNOTHERAPY PIPELINE

LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company
pioneering the oncology field…
 * November 11, 2021·


PROKARIUM SHARES PRECLINICAL PROOF-OF-CONCEPT DATA ON ITS MICROBIAL
IMMUNOTHERAPY BLADDER CANCER PROGRAM AT SITC 2021

LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company
pioneering the oncology field of…
 * November 2, 2021·


PROKARIUM PROMOTES LIVIJA DEBAN TO CHIEF SCIENTIFIC OFFICER TO DRIVE PIPELINE
EXPANSION IN CANCER IMMUNOTHERAPY

LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company
pioneering the oncology field…
 * October 12, 2021·


PROKARIUM AND WACKER BIOTECH SIGN MANUFACTURING CONTRACT FOR PROKARIUM’S
MICROBIAL IMMUNOTHERAPY FOR BLADDER CANCER PATIENTS

London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company
pioneering the oncology…
 * October 5, 2021·


PROKARIUM APPOINTS INDUSTRY VETERAN THOMAS ELDERED AS CHAIRMAN OF THE BOARD

LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering
the oncology field…
 * July 27, 2021·


PROKARIUM APPOINTS KRISTEN ALBRIGHT AS CHIEF EXECUTIVE OFFICER

LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering
the oncology field…
 * March 26, 2021·


PROKARIUM GAINS THE COVER OF THE INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE WITH
THE LATEST ENTERVAX PUBLICATION

Entervax is a novel bivalent oral vaccine against enteric fever, currently in a
phase 1…
 * October 27, 2020·


PROKARIUM CLOSES $21M SERIES B FINANCING ROUND AND STRENGTHENS BOARD

– Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of
Directors – Financing will…
 * July 14, 2020·


PROKARIUM OBTAINS NOTICE OF ALLOWANCE FOR US PATENT COVERING THE MODIFICATION OF
AN ATTENUATED STRAIN OF SALMONELLA ENTERICA SEROVAR TYPHI TO DEVELOP A VACCINE
AGAINST ENTERIC FEVER

Prokarium receives Notice of Allowance for US patent covering Entervax, an oral
bivalent vaccine against…
 * April 28, 2020·


PROKARIUM SIGNS AN EXCLUSIVE OPTION AGREEMENT WITH THE LAUSANNE UNIVERSITY
HOSPITAL (CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS – CHUV) FOR THE TREATMENT OF
NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Prokarium advances its oncology programme for bladder cancer signing an
exclusive option agreement with CHUV.
 * January 6, 2020·


PROKARIUM APPOINTS NEW ADVISORS TO INCREASE ONCOLOGY EXPERTISE

Prokarium welcomes Hyam Levitsky and David Holden as new advisors.
 * December 20, 2019·


PROKARIUM APPOINTS PETER MCGOWAN AS CHIEF FINANCIAL OFFICER

Prokarium welcomes Peter McGowan as new CFO.
 * November 26, 2019·


PROKARIUM ANNOUNCES MHRA ACCEPTANCE TO RUN A PHASE I TRIAL WITH ITS LEAD VACCINE
CANDIDATE ENTERVAX™

MHRA accepts a phase I trial with Prokarium's vaccine against enteric fever.
 * October 8, 2019·


PROKARIUM SECURES £4.6M FROM WELLCOME TO FUND THE CLINICAL DEVELOPMENT OF ITS
LEAD VACCINE PROGRAMME

Wellcome Trust funds Prokarium's vaccine against enteric fever.
 * January 10, 2019·


PROKARIUM STARTS 2019 WITH MOVE TO THE LONDON BIOSCIENCE INNOVATION CENTRE

Prokarium moves offices and laboratories to LBIC.
 * September 1, 2018·


PROKARIUM EXPANDS ITS TEAM TO DEVELOP ONCOLOGY PROGRAMMES, APPOINTING LIVIJA
DEBAN AS VICE PRESIDENT IMMUNOLOGY AND ONCOLOGY, AND KRISTEN ALBRIGHT AS VICE
PRESIDENT BD AND TRANSLATIONAL RESEARCH

Prokarium expands its team to develop a new microbial immunotherapy for solid
tumours.
 * February 26, 2018·


PROKARIUM SECURES $10 MILLION INVESTMENT FROM SAUDI, SWEDISH AND KOREAN
INVESTORS FOR CLINICAL DEVELOPMENT OF REVOLUTIONARY THERMOSTABLE VACCINES

Prokarium closes $10 million Series A round to develop thermostable vaccines.
 * July 25, 2016·


PROKARIUM RECEIVES £2M IN GOVERNMENT CONTRACTS TO DEVELOP NEW VACCINES AGAINST
EMERGING DISEASES AND BIOTERRORIST THREATS

Prokarium has received government funds to develop new vaccines.
 * July 15, 2016·


PROKARIUM AWARDS THE NEWTON FUND FOR THE DEVELOPMENT OF AN ORAL, THERMOSTABLE
ENTERIC FEVER VACCINE: SAVING LIVES AND SUPPORTING TOURISM IN MEXICO

Prokarium has awarded a £0.37m grant to develop an oral, bivalent vaccine
against enteric fever.
 * October 19, 2022·


PROKARIUM STRENGTHENS MANUFACTURING CAPABILITIES WITH APPOINTMENT OF PETER JUUL
MADSEN AS VICE PRESIDENT OF CMC

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company
pioneering the oncology field…
 * October 5, 2022·


PROKARIUM STRENGTHENS PATENT POSITION THROUGH NOTICE OF ALLOWANCE OF US PATENT
FOR IMMUNOTHERAPY PRIME IN COMBINATION WITH CELL THERAPIES

LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the
‘Company’), a biopharmaceutical…
 * March 2, 2022·


PROKARIUM EXERCISES OPTION FOR AN EXCLUSIVE WORLDWIDE LICENSE FOR THE USE OF
SALMONELLA IMMUNOTHERAPY IN THE TREATMENT OF BLADDER CANCER

LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering
the oncology field…



CAREERS

Situated within one of the largest hubs of life science and biotechnology
companies in the UK, Prokarium offers a multitude of career opportunities within
the microbial immunotherapy space. We are working hard to bring novel therapies
for bladder cancer and other solid tumours into the clinic to improve cancer
patients’ lives.

Join our team to unlock the next level of immuno-oncology!

At the moment we do not have any open positions.


London Bioscience Innovation Centre, 2 Royal College St, NW1 0NH, London, UK

 * info@prokarium.com
 * LinkedIn

Prokarium 2022 © All Rights Reserved.